Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alliqua, a New York-based biomedical products company, has completed the initial in-vitro permeation study for its transdermal pain patch project.
Subscribe to our email newsletter
Multiple formulations were evaluated, some of which achieved mean cumulative drug permeation amounts much higher than the existing market leading product.
On a comparative basis, the Alliqua patch exhibited competitive mean cumulative drug permeation with respect to the market leading product for the treatment of pain associated with post-herpetic neuralgia (PHN) or shingles.
The company believes that these results will provide it with options to pursue a 505(b)(2) type of a new drug application (NDA), in addition to a generic route for an abbreviated new drug application (ANDA).
Alliqua intends to proceed to the next stage of its developmental program basis these results.
There are plans to pursue a generic version of an existing pain management patch for the treatment of PHN also.
Alliqua president and director Richard Rosenblum said that Alliqua can become a high quality, low cost producer of this next generation transdermal pain patch, and garner significant market share by utilizing its proprietary hydrogel technology and existing facilities.